The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2025
   Review
2. A Clinical Care Algorithm for Detecting Progression in Multiple Sclerosis: RetratEMos Project.Cureus · 2024
   Article
3. Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.Journal of neurology · 2024
   Article
4. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.International journal of molecular sciences · 2023
   Review
5. The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe.Therapeutic advances in neurological disorders · 2023
   Article
6. Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.Neurology(R) neuroimmunology & neuroinflammation · 2023
   Review
7. Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey.Health science reports · 2022
   Article
8. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.Patient preference and adherence · 2022
   Review
9. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.Journal of neurology · 2021
   Review
10. A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm.JMIR medical informatics · 2020
    Article
11. Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy.PloS one · 2020
    Article
12. Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.Neurology and therapy · 2019
    Article
13. Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany.Frontiers in neurology · 2019
    Article
14. Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy.BMJ open · 2017
    Article
15. Interventions to improve the self-management support health professionals provide for people with progressive neurological conditions: protocol for a realist synthesis.BMJ open · 2017
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.